Fibroblast growth factor 21: a promising therapeutic target in obesity-related diseases

References

• Adams AC, Kharitonenkov A. FGF21: the center of a transcriptional nexus in metabolic regulation. Curr Diabetes Rev 2012;8(4):285-93
   Google Scholar
• Woo YC, Xu A, Wang Y, Lam KSL. Fibroblast Growth Factor 21 as an emerging metabolic regulator: clinical perspectives. Clin Endocrinol (Oxf) 2013;78(4):489-96
   PubMed Web of Science ®Google Scholar
• Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 2000;1492(1):203-6
   PubMed Web of Science ®Google Scholar
• Dushay J, Chui PC, Gopalakrishnan GS, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010;139(2):456-63
   PubMed Web of Science ®Google Scholar
• Zhang X, Yeung DC, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008;57(5):1246-53
   PubMed Web of Science ®Google Scholar
• Hojman P, Pedersen M, Nielsen AR, et al. Fibroblast Growth Factor-21 Is Induced in Human Skeletal Muscles by Hyperinsulinemia. Diabetes 2009;58(12):2797-801
   Google Scholar
• Yu H, Xia F, Lam KS, et al. Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans. Clin Chem 2011;57(5):691-700
   PubMed Web of Science ®Google Scholar
• Galman C, Lundasen T, Kharitonenkov A, et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab 2008;8(2):169-74
   PubMed Web of Science ®Google Scholar
• Heilbronn LK, Campbell LV, Xu A, Samocha-Bonet D. Metabolically protective cytokines adiponectin and fibroblast growth factor-21 are increased by acute overfeeding in healthy humans. PLoS One 2013;8(10):e78864
   Google Scholar
• Inagaki T, Dutchak P, Zhao G, et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 2007;5(6):415-25
   PubMed Web of Science ®Google Scholar
• Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005;115(6):1627-35
   PubMed Web of Science ®Google Scholar
• Tracey KJ. Editorial. Mol Med 2013;19:303
   Google Scholar
• Coskun T, Bina HA, Schneider MA, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008;149(12):6018-27
   PubMed Web of Science ®Google Scholar
• Adams AC, Halstead CA, Hansen BC, et al. LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys. PLoS One 2013;8(6):e65763
   PubMed Web of Science ®Google Scholar
• Gaich G, Chien JY, Fu H, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 2013;18(3):333-40
   PubMed Web of Science ®Google Scholar
• Dutchak Paul A, Katafuchi T, Bookout Angie L, et al. Fibroblast growth factor-21 regulates PPAR³ activity and the antidiabetic actions of thiazolidinediones. Cell 2012;148(3):556-67
   Google Scholar
• Badman MK, Pissios P, Kennedy AR, et al. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007;5(6):426-37
   PubMed Web of Science ®Google Scholar
• Lundåsen T, Hunt MC, Nilsson L-M, et al. PPARα is a key regulator of hepatic FGF21. Biochem Biophys Res Commun 2007;360(2):437-40
   PubMed Web of Science ®Google Scholar
• Ong KL, Rye KA, O’Connell R, et al. Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes. J Clin Endocrinol Metab 2012;97(12):4701-8
   Google Scholar
• Cuevas-Ramos D, Almeda-Valdes P, Meza-Arana CE, et al. Exercise increases serum fibroblast growth factor 21 (FGF21) levels. PLoS One 2012;7(5):e38022
   PubMed Web of Science ®Google Scholar
• Chen W, Hoo RL, Konishi M, et al. Growth hormone induces hepatic production of fibroblast growth factor 21 through a mechanism dependent on lipolysis in adipocytes. J Biol Chem 2011;286(40):34559-66
   PubMed Web of Science ®Google Scholar
• Qiang L, Accili D. FGF21 and the second coming of PPARgamma. Cell 2012;148(3):397-8
   PubMed Web of Science ®Google Scholar
• Andersen B, Beck-Nielsen H, Højlund K. Plasma FGF21 displays a circadian rhythm during a 72-h fast in healthy female volunteers. Clin Endocrinol 2011;75(4):514-19
   PubMed Web of Science ®Google Scholar
• Fon Tacer K, Bookout AL, Ding X, et al. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol 2010;24(10):2050-64
   PubMedGoogle Scholar
• Yie J, Hecht R, Patel J, et al. FGF21 N- and C-termini play different roles in receptor interaction and activation. FEBS Lett 2009;583(1):19-24
   PubMed Web of Science ®Google Scholar
• Yie J, Wang W, Deng L, et al. Understanding the physical interactions in the FGF21/FGFR/beta-Klotho complex: structural requirements and implications in FGF21 signaling. Chem Biol Drug Des 2012;79(4):398-410
   PubMed Web of Science ®Google Scholar
• Kurosu H, Choi M, Ogawa Y, et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 2007;282(37):26687-95
   PubMed Web of Science ®Google Scholar
• Potthoff MJ, Inagaki T, Satapati S, et al. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci USA 2009;106(26):10853-8
   PubMed Web of Science ®Google Scholar
• Xu J, Lloyd DJ, Hale C, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009;58(1):250-9
   PubMed Web of Science ®Google Scholar
• Yoon JC, Puigserver P, Chen G, et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 2001;413(6852):131-8
   PubMed Web of Science ®Google Scholar
• Berglund ED, Li CY, Bina HA, et al. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 2009;150(9):4084-93
   PubMed Web of Science ®Google Scholar
• Chau MD, Gao J, Yang Q, et al. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc Natl Acad Sci USA 2010;107(28):12553-8
   PubMed Web of Science ®Google Scholar
• Arner P, Pettersson A, Mitchell PJ, et al. FGF21 attenuates lipolysis in human adipocytes - a possible link to improved insulin sensitivity. FEBS Lett 2008;582(12):1725-30
   Google Scholar
• Shepherd PR, Kahn BB. Glucose transporters and insulin action--implications for insulin resistance and diabetes mellitus. N Engl J Med 1999;341(4):248-57
   PubMed Web of Science ®Google Scholar
• Lin Z, Tian H, Lam KS, et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab 2013;17(5):779-89
   PubMed Web of Science ®Google Scholar
• Goetz R. Metabolism: adiponectin – a mediator of specific metabolic actions of FGF21. Nat Rev Endocrinol 2013;9(9):506-8
   PubMed Web of Science ®Google Scholar
• Lee P, Brychta RJ, Linderman J, et al. Mild cold exposure modulates fibroblast growth factor 21 (FGF21) diurnal rhythm in humans: relationship between FGF21 levels, lipolysis, and cold-induced thermogenesis. J Clin Endocrinol Metab 2013;98(1):E98-102
   PubMed Web of Science ®Google Scholar
• Hondares E, Iglesias R, Giralt A, et al. Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J Biol Chem 2011;286(15):12983-90
   PubMed Web of Science ®Google Scholar
• Chartoumpekis DV, Habeos IG, Ziros PG, et al. Brown adipose tissue responds to cold and adrenergic stimulation by induction of FGF21. Mol Med 2011;17(7–8):736
   PubMed Web of Science ®Google Scholar
• Wente W, Efanov AM, Brenner M, et al. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 2006;55(9):2470-8
   PubMed Web of Science ®Google Scholar
• So WY, Cheng Q, Chen L, et al. High glucose represses beta-klotho expression and impairs fibroblast growth factor 21 action in mouse pancreatic islets: involvement of peroxisome proliferator-activated receptor gamma signaling. Diabetes 2013;62(11):3751-9
   Google Scholar
• Hart AW, Baeza N, Apelqvist A, Edlund H. Attenuation of FGF signalling in mouse beta-cells leads to diabetes. Nature 2000;408(6814):864-8
   Google Scholar
• Mashili FL, Austin RL, Deshmukh AS, et al. Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity. Diabetes Metab Res Rev 2011;27(3):286-97
   Google Scholar
• Izumiya Y, Bina HA, Ouchi N, et al. FGF21 is an Akt-regulated myokine. FEBS Lett 2008;582(27):3805-10
   PubMed Web of Science ®Google Scholar
• Camper-Kirby D, Welch S, Walker A, et al. Myocardial Akt activation and gender: increased nuclear activity in females versus males. Circ Res 2001;88(10):1020-7
   Google Scholar
• Hsuchou H, Pan W, Kastin AJ. The fasting polypeptide FGF21 can enter brain from blood. Peptides 2007;28(12):2382-6
   PubMed Web of Science ®Google Scholar
• Sarruf DA, Thaler JP, Morton GJ, et al. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes 2010;59(7):1817-24
   PubMed Web of Science ®Google Scholar
• Bookout AL, de Groot MH, Owen BM, et al. FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat Med 2013;19(9):1147-52
   PubMed Web of Science ®Google Scholar
• Cheung BM. Drug treatment for obesity in the post-sibutramine era. Drug Saf 2011;34(8):641-50
   Google Scholar
• Hale C, Chen MM, Stanislaus S, et al. Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance. Endocrinology 2012;153(1):69-80
   PubMed Web of Science ®Google Scholar
• Diaz-Delfin J, Hondares E, Iglesias R, et al. TNF-alpha represses beta-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. Endocrinology 2012;153(9):4238-45
   PubMed Web of Science ®Google Scholar
• Fisher FM, Chui PC, Antonellis PJ, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010;59(11):2781-9
   PubMed Web of Science ®Google Scholar
• Reinehr T, Woelfle J, Wunsch R, Roth CL. Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. J Clin Endocrinol Metab 2012;97(6):2143-50
   PubMed Web of Science ®Google Scholar
• Yang M, Dong J, Liu H, et al. Effects of short-term continuous subcutaneous insulin infusion on fasting plasma fibroblast growth factor-21 levels in patients with newly diagnosed type 2 diabetes mellitus. PLoS One 2011;6(10):e26359
   Google Scholar
• Semba RD, Sun K, Egan JM, et al. Relationship of serum fibroblast growth factor 21 with abnormal glucose metabolism and insulin resistance: the Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2012;97(4):1375-82
   Google Scholar
• Semba RD, Crasto C, Strait J, et al. Elevated serum fibroblast growth factor 21 is associated with hypertension in community-dwelling adults. J Hum Hypertens 2013;27(6):397-9
   Google Scholar
• Chen C, Cheung BM, Tso AW, et al. High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects. Diabetes Care 2011;34(9):2113-15
   PubMed Web of Science ®Google Scholar
• Tyynismaa H, Raivio T, Hakkarainen A, et al. Liver fat but not other adiposity measures influence circulating FGF21 levels in healthy young adult twins. J Clin Endocrinol Metab 2011;96(2):E351-5
   Google Scholar
• Planavila A, Redondo I, Hondares E, et al. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun 2013;4:2019
   PubMed Web of Science ®Google Scholar
• Liu SQ, Roberts D, Kharitonenkov A, et al. Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue. Sci. Rep 2013;3:2767
   PubMed Web of Science ®Google Scholar
• Cong WT, Ling J, Tian HS, et al. Proteomic study on the protective mechanism of fibroblast growth factor 21 to ischemia-reperfusion injury. Can J Physiol Pharmacol 2013;91(11):973-84
   Google Scholar
• Lin Z, Wu Z, Yin X, et al. Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One 2010;5(12):e15534
   PubMed Web of Science ®Google Scholar
• Chow WS, Xu A, Woo YC, et al. Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2013;33(10):2454-9
   PubMed Web of Science ®Google Scholar
• Eto K. FGF-21, a newcomer in the field of hypertension research. J Hum Hypertens 2013;27(6):343-4
   Google Scholar
• Yang SJ, Hong HC, Choi HY, et al. Effects of a three-month combined exercise programme on fibroblast growth factor 21 and fetuin-A levels and arterial stiffness in obese women. Clin Endocrinol (Oxf) 2011;75(4):464-9
   PubMed Web of Science ®Google Scholar
• Wang B, Yang G, Yang M, et al. Mitiglinide treatment may decreases plasma fibroblast growth factor-21 levels in individuals with new-onset T2DM. Cytokine 2012;57(2):300-3
   Google Scholar
• Mu J, Pinkstaff J, Li Z, et al. FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes 2012;61(2):505-12
   PubMed Web of Science ®Google Scholar
• Xu J, Bussiere J, Yie J, et al. Polyethylene glycol modified FGF21 engineered to maximize potency and minimize vacuole formation. Bioconjug Chem 2013;24(6):915-25
   PubMed Web of Science ®Google Scholar
• Camacho RC, Zafian PT, Achanfuo-Yeboah J, et al. Pegylated Fgf21 rapidly normalizes insulin-stimulated glucose utilization in diet-induced insulin resistant mice. Eur J Pharmacol 2013;715(1-3):41-5
   PubMed Web of Science ®Google Scholar
• Wang H, Xiao Y, Fu L, et al. High-level expression and purification of soluble recombinant FGF21 protein by SUMO fusion in Escherichia coli. BMC Biotechnol 2010;10:14
   PubMed Web of Science ®Google Scholar
• Veniant MM, Komorowski R, Chen P, et al. Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys. Endocrinology 2012;153(9):4192-203
   PubMed Web of Science ®Google Scholar
• Huang J, Ishino T, Chen G, et al. Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody. J Pharmacol Exp Ther 2013;346(2):270-80
   PubMed Web of Science ®Google Scholar
• Wu AL, Kolumam G, Stawicki S, et al. Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci Transl Med 2011;3(113):113ra126
   PubMed Web of Science ®Google Scholar
• Foltz IN, Hu S, King C, et al. Treating diabetes and obesity with an FGF21-mimetic antibody activating the betaKlotho/FGFR1c receptor complex. Sci Transl Med 2012;4(162):162ra153
   PubMed Web of Science ®Google Scholar
• Smith R, Duguay A, Bakker A, et al. FGF21 can be mimicked in vitro and in vivo by a novel anti-FGFR1c/beta-Klotho bispecific protein. PLoS One 2013;8(4):e61432
   Google Scholar
• Smith R, Duguay A, Weiszmann J, et al. A novel approach to improve the function of FGF21. BioDrugs 2013;27(2):159-66
   Google Scholar
• Kharitonenkov A, Wroblewski VJ, Koester A, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007;148(2):774-81
   PubMed Web of Science ®Google Scholar